{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T02:26:35Z","timestamp":1776306395772,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00296-021-04854-y","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T20:03:09Z","timestamp":1618257789000},"page":"141-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Approach to switching biologics in juvenile idiopathic arthritis: a real-life experience"],"prefix":"10.1007","volume":"42","author":[{"given":"\u015eerife G\u00fcl","family":"Karada\u011f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma G\u00fcl","family":"Demirkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahime","family":"Ko\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Figen","family":"\u00c7akmak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafize Emine","family":"S\u00f6nmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3594-7387","authenticated-orcid":false,"given":"Nuray","family":"Aktay Ayaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"4854_CR1","first-page":"622","volume":"29","author":"K Minden","year":"2002","unstructured":"Minden K, Niewerth M, Listing J, Zink A, German Study Group of Pediatric R (2002) Health care provision in pediatric rheumatology in Germany\u2013national rheumatologic database. J Rheumatol 29:622\u2013628","journal-title":"J Rheumatol"},{"key":"4854_CR2","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390\u2013392","journal-title":"J Rheumatol"},{"key":"4854_CR3","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Weiss PF, Beukelman T et al (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65:2499\u20132512","journal-title":"Arthritis Rheum"},{"key":"4854_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG et al (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63:465\u2013482","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4854_CR5","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/rheumatology\/kew209","volume":"55","author":"P Quartier","year":"2016","unstructured":"Quartier P (2016) Choice of biologic drug among children with juvenile idiopathic arthritis. Rheumatology (Oxford) 55:1534\u20131535","journal-title":"Rheumatology (Oxford)"},{"key":"4854_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T et al (2019) 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken) 71:717\u2013734","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4854_CR7","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A et al (2009) Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 61:658\u2013666","journal-title":"Arthritis Rheum"},{"key":"4854_CR8","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1136\/annrheumdis-2012-202031","volume":"72","author":"F McErlane","year":"2013","unstructured":"McErlane F, Beresford MW, Baildam EM et al (2013) Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis 72:1983\u20131988","journal-title":"Ann Rheum Dis"},{"key":"4854_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/rheumatology\/kev414","volume":"55","author":"A Consolaro","year":"2016","unstructured":"Consolaro A, Ravelli A (2016) Defining criteria for disease activity states in juvenile idiopathic arthritis. Rheumatology (Oxford) 55:595\u2013596","journal-title":"Rheumatology (Oxford)"},{"key":"4854_CR10","unstructured":"www.toraks.org.tr."},{"key":"4854_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/14712598.2020.1733524","volume":"20","author":"R Cimaz","year":"2020","unstructured":"Cimaz R, Maioli G, Calabrese G (2020) Current and emerging biologics for the treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther 20:725\u2013740","journal-title":"Expert Opin Biol Ther"},{"key":"4854_CR12","doi-asserted-by":"publisher","first-page":"5860","DOI":"10.2174\/0929867325666180522085716","volume":"25","author":"D Poddighe","year":"2018","unstructured":"Poddighe D, Romano M, Gattinara M, Gerloni V (2018) Biologics for the treatment of juvenile idiopathic arthritis. Curr Med Chem 25:5860\u20135893","journal-title":"Curr Med Chem"},{"key":"4854_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","volume":"1173","author":"A Marchesoni","year":"2009","unstructured":"Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173:837\u2013846","journal-title":"Ann N Y Acad Sci"},{"key":"4854_CR14","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","volume":"77","author":"L Kearsley-Fleet","year":"2018","unstructured":"Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, Isaacs JD, Hyrich KL, Group B-RC (2018) Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 77:1405\u20131412","journal-title":"Ann Rheum Dis"},{"key":"4854_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/rheumatology\/key195","volume":"57","author":"M Todoerti","year":"2018","unstructured":"Todoerti M, Favalli EG, Iannone F et al (2018) Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology (Oxford) 57:42\u201353","journal-title":"Rheumatology (Oxford)"},{"key":"4854_CR16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200437","author":"ML Mannion","year":"2020","unstructured":"Mannion ML, Xie F, Horton DB, Ringold S, Correll CK, Dennos A, Beukelman T, Investigators CR (2020) Biologic switching among non-systemic juvenile idiopathic arthritis patients: a cohort study in the childhood arthritis and rheumatology research alliance registry. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.200437","journal-title":"J Rheumatol"},{"key":"4854_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S2665-9913(20)30025-4","volume":"2","author":"L Kearsley-Fleet","year":"2020","unstructured":"Kearsley-Fleet L, Heaf E, Davies R et al (2020) Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study. Lancet Rheumatol 2:217\u2013226","journal-title":"Lancet Rheumatol"},{"key":"4854_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2011-201060","volume":"72","author":"MH Otten","year":"2013","unstructured":"Otten MH, Prince FH, Anink J et al (2013) Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann Rheum Dis 72:721\u2013727","journal-title":"Ann Rheum Dis"},{"key":"4854_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5152\/tpa.2015.2229","volume":"50","author":"\u00d6 Kasap\u00e7opur","year":"2015","unstructured":"Kasap\u00e7opur \u00d6, Barut K (2015) Treatment in juvenile rheumatoid arthritis and new treatment options treatments. Turk Pediatri Ars 50:1\u201310","journal-title":"Turk Pediatri Ars"},{"key":"4854_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3109\/14397595.2015.1083147","volume":"26","author":"T Kubota","year":"2016","unstructured":"Kubota T, Imanaka H, Takei S et al (2016) Disease activity score in 28 joints at 3 months after the initiation of biologic agent can be a predictive target for switching to the second biologic agent in patients with polyarticular juvenile idiopathic arthritis. Mod Rheumatol 26:358\u2013361","journal-title":"Mod Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04854-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04854-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04854-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T13:03:41Z","timestamp":1643893421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04854-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["4854"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04854-y","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"assertion":[{"value":"28 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare there are no conflicts of interest\u2014financial or otherwise\u2014related to the material presented herein.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with Good Clinical Practice Guidelines and the Declaration of Helsinki, with the necessary approval of the local ethics committee (ethics approval number: KAEK\/2019.01.06).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patients\u2019 legal guardians.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The patients\u2019 legal guardians provided written informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}